Journal of Clinical Lipidology · Oct 15, 2026
Lipoprotein-insulin resistance score is associated with atherosclerotic cardiovascular disease in liver transplant recipients
By Nguyen M, Razzaq R, Kim A et al.
BACKGROUND: Liver transplant (LT) recipients have increased atherogenic risk, which is difficult to quantify via available diagnostic tests. OBJECTIVE: The aim of the present study was to evaluate the diagnostic performance of the lipoprotein insulin resistance index (LP-IR) score, a composite biomarker of insulin resistance and metabolic risk, and its association with atherosclerotic cardiovascular disease (ASCVD) in LT recipients. METHODS: Analysis was performed in 218 LT recipients who were enrolled in a natural history study. Blood samples were collected after an overnight fast, and LP-IR was analyzed via nuclear magnetic resonance. The primary outcome was a composite endpoint consisting of new-onset coronary artery disease, nonfatal myocardial infarction, stroke, or sudden cardiac death. Cox regression models were constructed and adjusted to traditional ASCVD risk factors, liver disease, and immunosuppression. RESULTS: ASCVD was present in 47 LT recipients after a median follow-up of 47 months after study enrollment. In the adjusted analysis, LP-IR was significantly associated with future risk of the primary outcome, with a hazard ratio of 1.024 (95% CI 1.009 and 1.039, P = .002) that was independent of conventional risk factors. Combining LP-IR with diabetes improved the performance compared to either parameter alone. LP-IR had a higher diagnostic performance compared to the conventional lipid profile (low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, total cholesterol) and hepatic panel in predicting future risk of ASCVD. CONCLUSION: LP-IR is associated with future risk of ASCVD in LT recipients with or without diabetes and may have utility as a prognostic biomarker; however, study findings require development of a risk model and further validation.